Previous Close | 2.7200 |
Open | 2.6500 |
Bid | 2.8000 x 1200 |
Ask | 3.0000 x 1100 |
Day's Range | 2.6500 - 3.0000 |
52 Week Range | 1.7900 - 6.0300 |
Volume | |
Avg. Volume | 27,590 |
Market Cap | 71.381M |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.9210 |
Earnings Date | Mar 21, 2023 - Mar 27, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 26.00 |
Subscribe to Yahoo Finance Plus to view Fair Value for RPHM
IRVINE, Calif., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases, today announced that the company’s management team will participate at the SVB Securities Global Biopharma Conference. SVB Securities Global Biopharma ConferenceDate: Wednesday, Feb. 15, 2023Location: Virtual Presentation: 3:40 p.m. EST (webcast)
IRVINE, Calif., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted mavodelpar (REN001) Fast Track designation for long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) deficiency, one of the predominant genotypes in patients with long-chain f
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...